C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
3.040
+0.010 (0.33%)
At close: Mar 6, 2026, 4:00 PM EST
3.027
-0.013 (-0.44%)
After-hours: Mar 6, 2026, 7:14 PM EST
C4 Therapeutics Employees
C4 Therapeutics had 110 employees as of December 31, 2024. The number of employees decreased by 35 or -24.14% compared to the previous year.
Employees
110
Change (1Y)
-35
Growth (1Y)
-24.14%
Revenue / Employee
$326,791
Profits / Employee
-$954,491
Market Cap
296.64M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 222 |
| Puma Biotechnology | 172 |
| Cabaletta Bio | 151 |
| Nautilus Biotechnology | 124 |
| OmniAb | 114 |
| Immuneering | 54 |
| Cybin | 50 |
| ALX Oncology Holdings | 44 |
CCCC News
- 8 days ago - C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 11 days ago - C4 Therapeutics to Participate in Upcoming March Conferences - GlobeNewsWire
- 11 days ago - C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma - GlobeNewsWire
- 25 days ago - C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 7 weeks ago - C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways - GlobeNewsWire
- 3 months ago - Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss - Seeking Alpha
- 3 months ago - C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewsWire